Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 25, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: October 21, 2005
- Previous Holding: 18,292,670 ADRs
- New Holding: 18,344,636 ADRs
- Average Price: $50.53
- Reason: Movement in the fund.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that the Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of the reporting date.
- Confirm the average transaction price of $50.53 against market data for October 21, 2005.
- Review the specific disclosure rules (Rule 3.1.4R(1)(b)) under which this transaction was notified.
- Check for any subsequent filings regarding the holdings of Dr. J P Garnier and Dr. T Yamada.